Evidence map›Paper›PMID 39192178›Full record

ArticleBMC nephrology2024

Intermediate cystinosis: a case report of 10-year treatment with cysteamine.

Mariko Kawamura, Daisuke Katagiri, Yuuka Yamamoto, Keiki Shimada, Satomi Higashi, Masako Otani, Noriko Uesugi, Hideki Takano, Yukiko Shimizu, Tadashi Okamura

Abstract readCase Reports
In one paragraph

Article in BMC nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mariko KawamuraDepartment of Nephrology, Center Hospital of the National Center for Global Health and Medicine (NCGM), 1-21-1 Toyama Shinjuku-Ku, Tokyo, 162-8655, Japan.
Daisuke KatagiriDepartment of Nephrology, Center Hospital of the National Center for Global Health and Medicine (NCGM), 1-21-1 Toyama Shinjuku-Ku, Tokyo, 162-8655, Japan. dkatagiri@hosp.ncgm.go.jp.
Yuuka YamamotoDepartment of Ophthalmology, Center Hospital of the National Center for Global Health and Medicine (NCGM), 1-21-1 Toyama Shinjuku-Ku, Tokyo, 162-8655, Japan.
Keiki ShimadaDepartment of Nephrology, Center Hospital of the National Center for Global Health and Medicine (NCGM), 1-21-1 Toyama Shinjuku-Ku, Tokyo, 162-8655, Japan.
Satomi HigashiDepartment of Pediatrics, Saiseikai Yokohamashi Tobu Hospital, 3-6-1 Shimosueyoshi, Tsurumi-Ku, Yokohama-Shi, Kanagawa, 230-0012, Japan.
Masako OtaniDepartment of Diagnostic Pathology, International University of Health and Welfare, Mita Hospital, 1-4-3 Mita, Minato-Ku, Tokyo, 108-8329, Japan.
Noriko UesugiDepartment of Pathology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Hideki TakanoDepartment of Nephrology, Center Hospital of the National Center for Global Health and Medicine (NCGM), 1-21-1 Toyama Shinjuku-Ku, Tokyo, 162-8655, Japan.
Yukiko ShimizuDepartment of Laboratory Animal Medicine, Research Institute, National Center for Global Health and Medicine (NCGM), 1-21-1 Toyama Shinjuku-Ku, Tokyo, 162-8655, Japan.
Tadashi OkamuraDepartment of Laboratory Animal Medicine, Research Institute, National Center for Global Health and Medicine (NCGM), 1-21-1 Toyama Shinjuku-Ku, Tokyo, 162-8655, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCystinosis is a lysosomal storage disorder characterized by an autosomal recessive phenotype. Intermediate cystinosis, which progresses slowly and causes renal failure, accounts for approximately 5% of all cystinosis cases. Patients with intermediate cystinosis may not exhibit the typical symptoms of cystinosis, such as Fanconi syndrome and ocular symptoms. Because of its diverse clinical presentation and rarity, intermediate cystinosis can be difficult to diagnose. Additionally, few patients can tolerate cystine-depleting drugs, such as cysteamine, because of their complicated administration schedules and side effects. We report a case of intermediate cystinosis that was treated with cysteamine for 10 years. CASE PRESENTATION: Urinary abnormalities were first diagnosed when the patient was 3 years of age during a health examination specifically for 3-year-old children, which is unique to Japan. Cystinosis was diagnosed when the patient was 12 years of age. Cysteamine therapy was initiated and regular cystine concentration measurements were performed. Although proteinuria persisted, the patient's renal function progressed slowly. Two renal biopsies were performed, and multinucleated podocytes and cystine crystals without focal segmental glomerulosclerosis lesions were observed in the biopsy specimens. The patient's renal function remained stable.

conclusionsThis case of intermediate cystinosis was treated with cysteamine over the course of 10 years. Intermediate cystinosis requires an appropriate diagnosis and long-term treatment.

Indexed as

CysteamineCystine Depleting AgentsCystinosisChildChild, PreschoolHumansTreatment OutcomeCysteamineCystine Depleting AgentsCase reportCysteamineCystinosisLysosome

Identifiers

PMID39192178
PMCPMC11348783

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.